Featured Articles

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a proprietary…
Read More...

Boehringer Ingelheim and 3T Biosciences (“3T”) announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing…
Read More...

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory…
Read More...

MediLink Therapeutics ("MediLink"), announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug…
Read More...

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI)…
Read More...

GSK plc and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders,…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company’s supplemental Biologics License Application (sBLA) for Xolair…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application…
Read More...

Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies…
Read More...

Alkermes plc announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global…
Read More...

Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced a multi-target alliance to discover…
Read More...

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential…
Read More...

Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate the Japanese healthcare leader’s RNA-targeted drug…
Read More...

Ipsen and GENFIT announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual…
Read More...

Arvinas, Inc. and Pfizer Inc. announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination…
Read More...

Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi.…
Read More...

AbbVie Inc. and ImmunoGen, Inc. announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a…
Read More...

PRISM BioLab, Co. Ltd. announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly"). Under the agreement, PRISM and Lilly will…
Read More...

Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development…
Read More...

AbbVie announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody…
Read More...